<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicina (Kaunas)</journal-id><journal-id journal-id-type="iso-abbrev">Medicina (Kaunas)</journal-id><journal-id journal-id-type="pmc-domain-id">3494</journal-id><journal-id journal-id-type="pmc-domain">medicina</journal-id><journal-id journal-id-type="publisher-id">medicina</journal-id><journal-title-group><journal-title>Medicina</journal-title></journal-title-group><issn pub-type="ppub">1010-660X</issn><issn pub-type="epub">1648-9144</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10145512</article-id><article-id pub-id-type="pmcid-ver">PMC10145512.1</article-id><article-id pub-id-type="pmcaid">10145512</article-id><article-id pub-id-type="pmcaiid">10145512</article-id><article-id pub-id-type="pmid">37109600</article-id><article-id pub-id-type="doi">10.3390/medicina59040642</article-id><article-id pub-id-type="publisher-id">medicina-59-00642</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Systematic Review of Clinical Pharmacokinetics of Inhaled Antiviral</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6687-0461</contrib-id><name name-style="western"><surname>Alshammari</surname><given-names initials="MK">Mohammed Kanan</given-names></name><xref rid="af1-medicina-59-00642" ref-type="aff">1</xref><xref rid="c1-medicina-59-00642" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almutairi</surname><given-names initials="MS">Mohammed Salem</given-names></name><xref rid="af2-medicina-59-00642" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Althobaiti</surname><given-names initials="MD">Mohammed Dakhilallah</given-names></name><xref rid="af3-medicina-59-00642" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alsawyan</surname><given-names initials="WA">Watin Ahmed</given-names></name><xref rid="af4-medicina-59-00642" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alomair</surname><given-names initials="SA">Samar Abdulrahman</given-names></name><xref rid="af5-medicina-59-00642" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alwattban</surname><given-names initials="RR">Raghad Rsheed</given-names></name><xref rid="af6-medicina-59-00642" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al Khozam</surname><given-names initials="ZH">Zahra Hassan</given-names></name><xref rid="af2-medicina-59-00642" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alanazi</surname><given-names initials="TJ">Taif Jundi</given-names></name><xref rid="af7-medicina-59-00642" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alhuqyal</surname><given-names initials="AS">Abdullah S.</given-names></name><xref rid="af8-medicina-59-00642" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Darwish</surname><given-names initials="HSA">Hassan Saud Al</given-names></name><xref rid="af2-medicina-59-00642" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alotaibi</surname><given-names initials="AF">Abdulaziz Faisal</given-names></name><xref rid="af9-medicina-59-00642" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almutairi</surname><given-names initials="FN">Fahad Naif</given-names></name><xref rid="af10-medicina-59-00642" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alanazi</surname><given-names initials="AA">Abdullah Abdulrahman</given-names></name><xref rid="af10-medicina-59-00642" ref-type="aff">10</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Saleem</surname><given-names initials="Z">Zikria</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Haseeb</surname><given-names initials="A">Abdul</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-medicina-59-00642"><label>1</label>Department of Clinical Pharmacy, King Fahad Medical City, Riyadh 12211, Saudi Arabia</aff><aff id="af2-medicina-59-00642"><label>2</label>Maternity and Children Hospital, Dammam 32274, Saudi Arabia</aff><aff id="af3-medicina-59-00642"><label>3</label>Department of Nursing Adult Medical Surgical, Third Health Cluster, Riyadh 17451, Saudi Arabia</aff><aff id="af4-medicina-59-00642"><label>4</label>Medicine College, Qassim University, Ar Rass 58884, Saudi Arabia</aff><aff id="af5-medicina-59-00642"><label>5</label>Ministry of Health, Second Health Cluster, Riyadh 11375, Saudi Arabia</aff><aff id="af6-medicina-59-00642"><label>6</label>Department of Medicine, Qassim University, Ar Rass 51941, Saudi Arabia</aff><aff id="af7-medicina-59-00642"><label>7</label>Department of Clinical Pharmacy, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia</aff><aff id="af8-medicina-59-00642"><label>8</label>Department of Medicine, Shaqra University, Riyadh 17451, Saudi Arabia</aff><aff id="af9-medicina-59-00642"><label>9</label>Department of Medical Collage, Shaqra University, Dawadmi 17451, Saudi Arabia</aff><aff id="af10-medicina-59-00642"><label>10</label>Directorate of Health Affairs, Ministry of Health, Hafar Al-Batin 39511, Saudi Arabia</aff><author-notes><corresp id="c1-medicina-59-00642"><label>*</label>Correspondence: <email>ii_kanan101@outlook.com</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>59</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">434551</issue-id><elocation-id>642</elocation-id><history><date date-type="received"><day>02</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-01 05:25:40.503"><day>01</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medicina-59-00642.pdf"/><abstract><p><italic toggle="yes">Background and Objectives</italic>: The study of clinical pharmacokinetics of inhaled antivirals is particularly important as it helps one to understand the therapeutic efficacy of these drugs and how best to use them in the treatment of respiratory viral infections such as influenza and the current COVID-19 pandemic. The article presents a systematic review of the available pharmacokinetic data of inhaled antivirals in humans, which could be beneficial for clinicians in adjusting doses for diseased populations. <italic toggle="yes">Materials and Methods</italic>: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. A comprehensive literature search was conducted using multiple databases, and studies were screened by two independent reviewers to assess their eligibility. Data were extracted from the eligible studies and assessed for quality using appropriate tools. <italic toggle="yes">Results</italic>: This systematic review evaluated the pharmacokinetic parameters of inhaled antiviral drugs. The review analyzed 17 studies, which included Zanamivir, Laninamivir, and Ribavirin with 901 participants, and found that the non-compartmental approach was used in most studies for the pharmacokinetic analysis. The outcomes of most studies were to assess clinical pharmacokinetic parameters such as the Cmax, AUC, and t1/2 of inhaled antivirals. <italic toggle="yes">Conclusions</italic>: Overall, the studies found that the inhaled antiviral drugs were well tolerated and exhibited favorable pharmacokinetic profiles. The review provides valuable information on the use of these drugs for the treatment of influenza and other viral respiratory infections.</p></abstract><kwd-group><kwd>systematic review</kwd><kwd>clinical use</kwd><kwd>pharmacokinetics</kwd><kwd>inhaled</kwd><kwd>antiviral</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-medicina-59-00642"><title>1. Introduction</title><p>Clinical pharmacokinetics studies are crucial in the context of inhaled antivirals. They clarify the therapeutic efficacy of these medications and the optimal ways to administer them to treat respiratory viral diseases such as influenza and the current COVID-19 [<xref rid="B1-medicina-59-00642" ref-type="bibr">1</xref>,<xref rid="B2-medicina-59-00642" ref-type="bibr">2</xref>]. Inhaled antivirals refer to a class of drugs that are delivered directly to the respiratory tract through inhalation, as opposed to being taken orally or intravenously [<xref rid="B3-medicina-59-00642" ref-type="bibr">3</xref>]. This method of administration offers several advantages over other routes, including a faster onset of action, more direct and localized exposure to the site of infection, and lower systemic drug exposure and associated side effects [<xref rid="B4-medicina-59-00642" ref-type="bibr">4</xref>]. Although there are certain advantages to inhaled medication administration, this route also has significant drawbacks, particularly when it comes to achieving accurate and repeatable doses [<xref rid="B5-medicina-59-00642" ref-type="bibr">5</xref>]. The amount of medication that is delivered to the lungs and, consequently, the therapeutic effect can be influenced by a number of variables. These include the size of the drug particles, the shape of the inhaler device, patient technique, anatomy of the airway, pathophysiological effects of acute and chronic diseases, and environmental factors [<xref rid="B6-medicina-59-00642" ref-type="bibr">6</xref>,<xref rid="B7-medicina-59-00642" ref-type="bibr">7</xref>].</p><p>The pharmacokinetics of inhaled antivirals can be divided into three main phases: deposition, absorption, and elimination [<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>]. Deposition refers to the amount of drug that is delivered to the respiratory tract and deposited in the lungs. The optimal drug deposition site after inhalation varies based on the indication and the physical and chemical characteristics of the drug [<xref rid="B9-medicina-59-00642" ref-type="bibr">9</xref>]. Absorption refers to the process by which the drug moves from the lungs into the site of action, where it can then exert its therapeutic effect [<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>]. The rapid absorption of small molecules within alveolar cells can make it challenging to measure plasma drug concentrations after inhalation. This sets the pharmacokinetic study of inhaled antimicrobials apart from traditional pharmacokinetic studies, as it requires a highly sensitive assay and frequent sampling over a short period to accurately determine the absorption rate [<xref rid="B11-medicina-59-00642" ref-type="bibr">11</xref>]. The elimination of inhaled antivirals from the body can occur via multiple pathways, including mucociliary clearance, removal via alveolar macrophages, metabolism, excretion, penetration into systemic circulation, and exhalation. The specific pathways used for elimination may vary based on factors such as the specific antiviral, patient characteristics, and the disease state [<xref rid="B12-medicina-59-00642" ref-type="bibr">12</xref>]. It is important to consider the pharmacokinetics of inhaled antivirals when determining the dosing regimen for these drugs. The goal is to achieve therapeutic concentrations of the drug in the respiratory tract, while minimizing systemic exposure and the associated side effects [<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>]. Understanding the interplay between drug delivery, absorption, and elimination is essential for optimizing dosing regimens and ensuring that patients receive the maximum therapeutic benefit from these drugs.</p><p>Inhaled antivirals offered several advantages over oral or intravenous formulations of these drugs during the COVID-19 pandemic [<xref rid="B14-medicina-59-00642" ref-type="bibr">14</xref>]. First, inhaled drugs reach the site of infection more quickly, leading to a faster onset of action and improved therapeutic outcomes. Second, inhaled drugs are delivered directly to the respiratory tract, which minimizes systemic exposure and reduces the risk of side effects that may be associated with oral or intravenous formulations of these drugs [<xref rid="B15-medicina-59-00642" ref-type="bibr">15</xref>]. In addition, inhaled antivirals have been shown to be effective in reducing the severity and duration of respiratory viral infections, as well as reducing the risk of hospitalization and death in some cases [<xref rid="B16-medicina-59-00642" ref-type="bibr">16</xref>]. This is particularly important for individuals who are at high risk of complications from these infections, such as the elderly, young children, and individuals with underlying medical conditions [<xref rid="B17-medicina-59-00642" ref-type="bibr">17</xref>]. Dry powder inhalers (DPIs), including the Diskhaler and Rotahaler, are significant drug delivery devices for inhaled antiviral drugs such as Zanamivir, Laninamivir, and Ribavirin. DPIs are particularly useful for delivering drugs to the lungs, where respiratory viral infections are most prevalent.</p><p>The main objective of this systematic review was to fill the gap in knowledge regarding the pharmacokinetics of inhaled antiviral drugs. While there is a significant amount of literature on the pharmacokinetics of systemically administered antivirals, there is a lack of comprehensive reviews on the pharmacokinetics of inhaled antivirals. The authors therefore aimed to systematically review the existing literature to provide a comprehensive overview of the pharmacokinetic aspects of inhaled antivirals in humans. To date, no systematic review has been conducted to determine the PK parameters of inhaled antivirals. This review endeavors to systematically gather, summarize, and analyze all of the available PK data of inhaled antivirals in the human population, which could be beneficial for clinicians in adjusting the doses in both healthy and diseased populations.</p></sec><sec id="sec2-medicina-59-00642"><title>2. Materials and Methods</title><p>The methodology used for conducting this systematic review on the pharmacokinetics of inhaled antivirals in humans was the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.</p><sec id="sec2dot1-medicina-59-00642"><title>2.1. Identification of the Research Question</title><p>The research question was identified, which was clear, specific, and focused on the pharmacokinetics of inhaled antivirals in humans following the inhalation route of administration.</p></sec><sec id="sec2dot2-medicina-59-00642"><title>2.2. Literature Search</title><p>A comprehensive literature search was conducted using multiple databases, such as PubMed, Google Scholar, Science Direct, Embase, and the Cochrane Library, to identify relevant studies. The search was performed using relevant keywords and Medical Subject Headings (MeSH) terms. These databases were searched with the following key terms: &#8216;Inhaled antivirals&#8217;, &#8216;antivirals&#8217;, &#8216;Inhaled antimicrobial&#8217;, &#8216;Inhaled antibiotic&#8217;, &#8216;Respiratory Infections&#8217;, &#8216;clinical pharmacokinetic&#8217;, and &#8216;pharmacokinetic&#8217; with &#8220;AND&#8221; or &#8220;OR&#8221;. An overview of the final search strategy with MeSH terms and text words for each of the four domains is described in <xref rid="medicina-59-00642-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot3-medicina-59-00642"><title>2.3. Inclusion and Exclusion Criteria</title><p>The inclusion criteria were clearly defined and included studies that examined the PK parameters of inhaled antivirals in humans following inhalation. The studies were limited to those conducted in healthy and diseased populations. Only peer-reviewed articles in the English language and at least one reported PK parameter that specified an inhaled antiviral were included. Both randomized control trials (RCTs) and observational studies were included. Moreover, there was no limitation on the publication year, whereas the studies that did not meet the inclusion criteria or those that did not provide PK data of inhaled antivirals were excluded.</p></sec><sec id="sec2dot4-medicina-59-00642"><title>2.4. Study Selection</title><p>The studies identified through the literature search were screened by two independent reviewers to assess their eligibility. Any disagreements were resolved through consensus or by a third reviewer. After evaluating all of the databases, studies were screened for duplication detection, which were then deleted, respectively. The articles were excluded after screening title and abstract. Review articles and book chapters were also excluded.</p></sec><sec id="sec2dot5-medicina-59-00642"><title>2.5. Data Extraction</title><p>Data were extracted from the eligible studies using a standardized data extraction form. The data included information on study reference, design, research objectives, outcome measures, spray device, model structure, population characteristics, sample size, drug name, dosing practice, and pharmacokinetic parameters, including plasma concentration time curve (AUC), peak concentration of antivirals in plasma (Cmax), half-life (T1/2), volume of distribution (Vd), and clearance (Cl). The author&#8217;s name with publication year and the number were also mentioned.</p></sec><sec id="sec2dot6-medicina-59-00642"><title>2.6. Quality Assessment</title><p>The quality of the eligible studies was assessed using appropriate tools, such as the Cochrane Risk of Bias tool for randomized controlled trials and the Newcastle&#8211;Ottawa Scale (NOS) for cohort studies.</p></sec><sec id="sec2dot7-medicina-59-00642"><title>2.7. Data Synthesis and Reporting</title><p>The extracted data were synthesized and analyzed to provide a comprehensive overview of the PK aspects of inhaled antivirals in humans following inhalation.</p></sec></sec><sec sec-type="results" id="sec3-medicina-59-00642"><title>3. Results</title><sec id="sec3dot1-medicina-59-00642"><title>3.1. Literature Search</title><p>A total of 1102 relevant published articles were identified from the gray literature and databases such as PubMED, ScienceDirect, Web of Science, and EMBASE. Of 1695 articles, 341 articles were screened after the exclusion of duplicates. On the basis of the exclusion and inclusion criteria, 1050 articles were excluded after the screening of the titles and abstracts of the articles. Seventy-eight of the included articles that did not contain any information regarding the pharmacokinetics of inhaled antiviral agents were excluded. After the screening of abstracts and full-text articles, 142 articles were excluded for the following reasons: non-English (N = 22), articles on other modes of administration (N = 45), inappropriate interventions (N = 34), review articles (N = 5), and animal studies (N = 36). Data extraction was performed for 17 full-text articles with data on the PKs of inhaled antivirals (<xref rid="medicina-59-00642-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3dot2-medicina-59-00642"><title>3.2. Characteristics of Studies</title><p>Seventeen articles met the inclusion criteria for this systematic review [<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>,<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>,<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>,<xref rid="B18-medicina-59-00642" ref-type="bibr">18</xref>,<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>,<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>,<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>,<xref rid="B22-medicina-59-00642" ref-type="bibr">22</xref>,<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>,<xref rid="B24-medicina-59-00642" ref-type="bibr">24</xref>,<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>,<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>,<xref rid="B27-medicina-59-00642" ref-type="bibr">27</xref>,<xref rid="B28-medicina-59-00642" ref-type="bibr">28</xref>,<xref rid="B29-medicina-59-00642" ref-type="bibr">29</xref>,<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>,<xref rid="B31-medicina-59-00642" ref-type="bibr">31</xref>]. The characteristics of selected articles are listed in <xref rid="medicina-59-00642-t002" ref-type="table">Table 2</xref>. The majority of the articles studied the pharmacokinetic parameters of Zanamivir and Laninamivir. Of 17 articles, 11 studies were randomized controlled trials (RCTs) [<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>,<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>,<xref rid="B18-medicina-59-00642" ref-type="bibr">18</xref>,<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>,<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>,<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>,<xref rid="B22-medicina-59-00642" ref-type="bibr">22</xref>,<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>,<xref rid="B24-medicina-59-00642" ref-type="bibr">24</xref>,<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>,<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>], followed by preliminary studies [<xref rid="B27-medicina-59-00642" ref-type="bibr">27</xref>,<xref rid="B28-medicina-59-00642" ref-type="bibr">28</xref>], open-label studies [<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>,<xref rid="B29-medicina-59-00642" ref-type="bibr">29</xref>], prospective studies [<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>], and non-randomized studies [<xref rid="B31-medicina-59-00642" ref-type="bibr">31</xref>]. The non-compartmental approach was used in 12 studies for the pharmacokinetic analysis. The outcomes of most of the studies were to assess the clinical pharmacokinetics parameters such as maximum concentration (Cmax), area under curve (AUC), and half-life (t1/2) of inhaled antivirals. A total of 901 patients participated in the studies. The majority of the studies used a Rotahaler and Diskhaler for the administration of the drug [<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>,<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>,<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>,<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>,<xref rid="B31-medicina-59-00642" ref-type="bibr">31</xref>].</p></sec><sec id="sec3dot3-medicina-59-00642"><title>3.3. Quality Assessment of the Studies</title><p>The quality of the studies was assessed and summarized in the <xref rid="app1-medicina-59-00642" ref-type="app">Supplementary File (Tables S1 and S2</xref>). On the basis of the NOS, five articles were rated as 7 and one article scored 6. Overall, the quality score for prospective and preliminary studies was seven. For RCT, the Cochrane bias tool assessed that most of the domains were at low risk.</p><p>Pharmacokinetic parameters of inhaled antiviral drugs.</p></sec><sec id="sec3dot4-medicina-59-00642"><title>3.4. Zanamivir</title><p>In most of the studies, the Zanamivir was administered via Diskhaler (<xref rid="medicina-59-00642-t003" ref-type="table">Table 3</xref>) [<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>,<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>,<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>,<xref rid="B31-medicina-59-00642" ref-type="bibr">31</xref>]. Doses utilized in the studies ranged from 4 mg to 16 mg and were administered in either a single dose or multiple doses. However, Weller and his colleagues support the use of Rotahaler/Rotacap especially in an influenza pandemic [<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>]. The clearance of this drug was 49 L/h via Rotahaler while the clearance was 54 L/h via Diskhaler. Overall, the half-life ranged from 2&#8211;3 h when administered via Diskhaler [<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>,<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>,<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>]. In another study, single doses of 4, 8, and 16 mg and multiple doses of 16 mg BID on Day 1 followed by QID for 6 days of Zanamivir were well tolerated when administered via nebulizer and dry powder inhaler [<xref rid="B18-medicina-59-00642" ref-type="bibr">18</xref>].</p><p>A dose of 10 mg of Zanamivir was well tolerated and safe in pediatric patients [<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>,<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>]. Zenamivir was administered twice daily for 5 days intranasally and via being inhaled orally, and the maximum concentration was achieved by 1.5 h after dosing [<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>]. However, another study reported that the systemic absorption of Zanamivir following oral inhalation or intranasal administration was low [<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>].</p></sec><sec id="sec3dot5-medicina-59-00642"><title>3.5. Laninamivir</title><p>The majority of the studies reported that the dose of 40 mg of prodrug CS-8958 was well tolerated and exhibited a PK profile, suggesting the potential for the parameters of Laninamivir and its prodrug CS-8958 in healthy participants and patients with comorbidities (<xref rid="medicina-59-00642-t003" ref-type="table">Table 3</xref>) [<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>,<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>]. The maximum concentration of CS-8958 ranged from 12.8 to 433 ng/mL. Ishizuka and her colleagues reported that CS-8958 was well tolerated in patients with renal impairment [<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>]. The PK parameters such as AUC0-inf, Cmax, and time to Cmax of CS-8958 did not change with the degree of renal impairment; however, the t1/2 of CS-8958 gradually increased with increased renal insufficiency [<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>].</p><p>A study conducted in adults and pediatric patients reported that the volume of distribution of Laninamivir Octanoate (LO) and metabolic clearance of LO were altered with body weight [<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>]. For a single inhaled dose of 40 mg of LO, the Laninamivir amount was evaluated to be approximately 0.46 mg in the respiratory tract compartment at 1-week post-dose [<xref rid="B29-medicina-59-00642" ref-type="bibr">29</xref>].</p><p>The concentrations of Laninamivir in the epithelial lining fluid (ELF) and bronchoalveolar lavage (BAL) fluid samples were assessed by Ishizuka and her colleagues to study the drug distribution in airways [<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>]. The ELF concentration profiles of Laninamivir showed the potential long-lasting effect for the treatment of patients with influenza virus infection [<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>].</p></sec><sec id="sec3dot6-medicina-59-00642"><title>3.6. Ribavirin</title><p>The studies reported that the utilization of aerosolized Ribavirin was well tolerated in healthy volunteers and the patient with other conditions (<xref rid="medicina-59-00642-t003" ref-type="table">Table 3</xref>) [<xref rid="B24-medicina-59-00642" ref-type="bibr">24</xref>,<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>,<xref rid="B27-medicina-59-00642" ref-type="bibr">27</xref>,<xref rid="B28-medicina-59-00642" ref-type="bibr">28</xref>]. Dumont and his colleagues developed dry powder particles using PRINT technology. The doses of 60 mg and 120 mg followed by 30 mg twice daily for 14 days were administered via Rotahaler to healthy volunteers and to those with chronic obstructive pulmonary disease (COPD). They concluded that PRINT formulation was an efficient and convenient mode of administration of the drug to the lungs while minimizing systemic exposure [<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>]. Moreover, a randomized, placebo-controlled study was performed to evaluate the safety and pharmacokinetics of inhaled Ribavirin [<xref rid="B24-medicina-59-00642" ref-type="bibr">24</xref>]. The participants were recruited in four groups where they received different doses. Cohort 1 received 50 mg/mL Ribavirin/placebo (10 mL total volume); Cohort 2 received 50 mg/mL Ribavirin/placebo (20 mL total volume); Cohort 3 received 100 mg/mL Ribavirin/placebo (10 mL total volume); and Cohort 4 received 100 mg/mL Ribavirin/placebo (20 mL total volume). The mean maximum observed concentration (Cmax) and area under the curve (AUC) values were higher in Cohort 4, whereas Cohorts 2 and 3 showed similar PK values. The data support the development of Ribavirin as an empirical treatment option in patients with coronavirus.</p><p>In pediatric patients with suspected respiratory syncytial virus infection, patients received aerosolized Ribavirin of 60 mg/mL for 2 h periods TID for 3 days [<xref rid="B27-medicina-59-00642" ref-type="bibr">27</xref>]. After the first dose, the mean peak Ribavirin level ranged from 1725 to 2179 mol/L in secretions and 3.8 mol/L in plasma. Ribavirin was rapidly cleared with a mean t1/2 of 1.9 h.</p></sec><sec id="sec3dot7-medicina-59-00642"><title>3.7. Rimantadine</title><p>The safety and pharmacokinetics of rimantadine were assessed by administering it via small-particle aerosol and oral inhalation in healthy volunteers and volunteers with acute influenza virus infection [<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>]. Rimantadine was delivered at a concentration of 20 &#181;g/L every 4&#8211;12 h and 40 &#181;g/L every 15 min to 4 h of air. The clearance of rimantadine ranged from 25.3 to 29.9 L/h and Vd ranged from 904 to 906 L. Some of the participants experienced nasal burning and irritation. This study concluded that a concentration of 20 &#181;g/liter of air was well tolerated for up to 12 h by normal volunteers as well as in those with acute influenza virus infection.</p></sec></sec><sec sec-type="discussion" id="sec4-medicina-59-00642"><title>4. Discussion</title><p>In this systematic review, we have investigated the pharmacokinetic parameters of inhaled antivirals. The non-compartmental model was used in the majority of the studies. Non-compartmental modeling is commonly used to study the pharmacokinetic (PK) parameters of drugs because it provides a simple and efficient way to analyze drug concentration&#8211;time data without making any assumptions about the underlying biological system [<xref rid="B32-medicina-59-00642" ref-type="bibr">32</xref>]. This makes it particularly useful when the pharmacokinetics of a drug are not well understood or when the data are limited. The studies utilized dry powder inhalers (DPI) such as Diskhaler and Rotahaler for drug delivery. DPIs are used to deliver the drug directly to the lungs and are preferred for different types of drugs and inspiratory flow rates [<xref rid="B33-medicina-59-00642" ref-type="bibr">33</xref>]. They are easy to use and have a lower environmental impact compared to other types of inhalers. Overall, drug powder inhalers can have a significant impact on the pharmacokinetic parameters of a drug, which can affect its overall effectiveness and safety. It is important to carefully consider the particle size and density of the drug powder when designing inhaler devices to ensure that medications are delivered effectively and efficiently to the lungs.</p><p>While emerging respiratory infectious diseases and associated morbidity and mortality have abated, they remain substantial threats to the public as well as scientific/medical communities [<xref rid="B34-medicina-59-00642" ref-type="bibr">34</xref>,<xref rid="B35-medicina-59-00642" ref-type="bibr">35</xref>]. Among highly contagious respiratory infections, influenza is responsible for significant morbidity and mortality worldwide [<xref rid="B36-medicina-59-00642" ref-type="bibr">36</xref>]. Neuraminidase inhibitors such as oseltamivir, Zanamivir, and Laninamivir have been the mainstay of influenza antiviral treatment over the past few decades [<xref rid="B37-medicina-59-00642" ref-type="bibr">37</xref>,<xref rid="B38-medicina-59-00642" ref-type="bibr">38</xref>]. Zanamivir is a widely used drug as a therapeutic and prophylactic and is currently available in dry powder inhalation and IV formulation. The recommended dose for prophylaxis is 10 mg once daily for up to 28 days in adults and for pediatric patients aged above 5 years treatment is 10 mg twice daily for 5 days [<xref rid="B39-medicina-59-00642" ref-type="bibr">39</xref>]. In a study, it was reported that about 12% of the dose is absorbed systemically after inhaled administration and reached Cmax within 2 h [<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>]. Approximately 78% and 13% of the drug Zanamivir was deposited in the oropharynx and the lungs when administered intranasally [<xref rid="B18-medicina-59-00642" ref-type="bibr">18</xref>,<xref rid="B40-medicina-59-00642" ref-type="bibr">40</xref>]. In these studies, Zanamivir was considered to be a well-tolerated antiviral drug administered intranasally by healthy volunteers and patients with influenza.</p><p>Furthermore, Laninamivir, a substituted compound of Zanamivir, is a therapeutic agent for the prophylaxis and treatment of viral infections [<xref rid="B41-medicina-59-00642" ref-type="bibr">41</xref>,<xref rid="B42-medicina-59-00642" ref-type="bibr">42</xref>]. Among the prodrugs of Laninamivir, Laninamivir Octanoate (LO), also known as CS-8958, is the most potent drug for the treatment of influenza available in only orally inhaled formulation, which delivers the drug directly to the respiratory tract [<xref rid="B40-medicina-59-00642" ref-type="bibr">40</xref>]. Multisite studies have reported that LO has prophylactic as well as therapeutic efficacy against highly pathogenic H5N1 influenza viruses [<xref rid="B43-medicina-59-00642" ref-type="bibr">43</xref>,<xref rid="B44-medicina-59-00642" ref-type="bibr">44</xref>]. A single inhaled dose of 20 mg in pediatric patients &lt;10 years old or 40 mg in adults and children &gt;10 years old of LO was found to be more effective and safe over oseltamivir regimens concerning mean time to illness alleviation [<xref rid="B45-medicina-59-00642" ref-type="bibr">45</xref>]. The pharmacokinetic profile of LO has been assessed in healthy adults, patients with renal insufficiency, elderly subjects, and patients with influenza infection [<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>,<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>,<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>]. Linear PKs of Laninamivir and its prodrug was observed across a wide range of doses (5&#8211;120 mg) by Yoshihara et al. [<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>]. The peak of plasma concentration was achieved after dosing and then declined with a half-life of approximately 2 h, whereas the peak of plasma Laninamivir concentration was achieved at approximately 4 h post-dose and declined with a half-life of approximately 3 days [<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>,<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>]. The findings documented that the single inhaled dose of LO was sufficient to treat influenza virus infection; moreover, it may show better compliance in patients with influenza infection and this feature may be favorable for prophylactic use.</p><p>Besides influenza virus infection, respiratory syncytial virus (RSV) is the most important cause of serious lower respiratory tract infections (LRTIs), especially in pediatric patients [<xref rid="B46-medicina-59-00642" ref-type="bibr">46</xref>,<xref rid="B47-medicina-59-00642" ref-type="bibr">47</xref>]. Ribavirin, an inosine monophosphate dehydrogenase inhibitor, is currently recommended for the treatment of LRTIs in hospitalized patients with RSV [<xref rid="B48-medicina-59-00642" ref-type="bibr">48</xref>]. Aerosolized Ribavirin has shown significant clinical improvement in patients with RSV [<xref rid="B49-medicina-59-00642" ref-type="bibr">49</xref>,<xref rid="B50-medicina-59-00642" ref-type="bibr">50</xref>]. The PK results are promising, specifically in the context of coronavirus and intensive care settings where patients&#8217; ability to swallow is compromised, and the delivery of a drug to the site of infection (respiratory tract) provides advantages over oral and intravenous formulations [<xref rid="B51-medicina-59-00642" ref-type="bibr">51</xref>]. Ribavirin exhibits two rapid phases, i.e., absorption and distribution and a long terminal clearance phase [<xref rid="B52-medicina-59-00642" ref-type="bibr">52</xref>,<xref rid="B53-medicina-59-00642" ref-type="bibr">53</xref>].</p><p>Aerosolization provides the direct delivery of antiviral drugs to the site via the respiratory tract in a desirable amount to remove pathogenic organisms [<xref rid="B54-medicina-59-00642" ref-type="bibr">54</xref>]. This method of drug administration usually results in a higher concentration of the drug at the site of infection than systematic administration does, and may minimize systemic toxicities [<xref rid="B55-medicina-59-00642" ref-type="bibr">55</xref>]. Rimantadine has better antiviral activity against influenza A virus strains than amantadine. Hayden et al. have previously reported that the use of rimantadine delivered via an ultrasonic nebulizer in subjects with influenza A virus is well tolerated except for minor complaints, i.e., unpleasant smell or taste [<xref rid="B56-medicina-59-00642" ref-type="bibr">56</xref>]. However, Atmar et al. reported that nasal burning or irritation was the most common side effect associated with rimantadine SPA [<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>]. About 45.6% of the dose of rimantadine reached the systemic circulation after SPA administration, and the mean peak levels in serum were 8.6-fold lower [<xref rid="B57-medicina-59-00642" ref-type="bibr">57</xref>]. The studies found that Ribavirin was rapidly cleared, with a t1/2 of 1.9 h. SPA delivery of antiviral drugs has been shown to be effective in the treatment of other respiratory viral infections [<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>,<xref rid="B58-medicina-59-00642" ref-type="bibr">58</xref>].</p><p>The novelty of this systematic review lies in its comprehensive and systematic approach to synthesizing the available literature on the clinical pharmacokinetics of inhaled antiviral drugs. The review provides a detailed and up-to-date summary of the pharmacokinetic parameters of various inhaled antiviral drugs, which can help to inform clinical decision-making and optimize the use of these drugs in the treatment of respiratory viral infections. Additionally, the review highlights the gaps in current knowledge and identifies areas for further research, which can guide future studies in this field. Overall, this systematic review tried to provide details of the inhaled antiviral agents, and offered a few inhaled antiviral drugs for the treatment of respiratory viral infections. A limited amount of data on the clinical pharmacokinetics of inhaled antiviral drugs is still a matter of concern. Several factors such as inspiratory flow rate, tidal volume, and presence and degree of airway obstruction can affect the concentration of antimicrobials [<xref rid="B40-medicina-59-00642" ref-type="bibr">40</xref>]. However, the data on these factors are limited. Few studies are performed during the preclinical and clinical stages. It is hereby recommended that more studies are required for the further development of a novel aerosolized drug.</p></sec><sec sec-type="conclusions" id="sec5-medicina-59-00642"><title>5. Conclusions</title><p>The clinical pharmacokinetics (PKs) of inhaled antivirals have been studied using non-compartmental models. Despite the aforementioned factors, clinical PK studies of inhaled antivirals have shown that they result in high concentrations in the respiratory tract, with relatively low systemic exposure, and reduce the risk of toxicity, which leads to the development of such advanced formulations and aids in modifying advanced aerosolization devices. Moreover, limited data were available on the pharmacokinetic parameters of existing inhaled drugs. Therefore, further studies, especially randomized controlled trials, are required to obtain a PK profile of inhaled antiviral drugs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-medicina-59-00642"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/medicina59040642/s1">https://www.mdpi.com/article/10.3390/medicina59040642/s1</uri>, Table S1: Quality assessment of cohort studies; Table S2: Risk of bias assessment for randomized controlled trials.</p><supplementary-material id="medicina-59-00642-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medicina-59-00642-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>M.K.A., M.S.A., M.D.A., W.A.A., S.A.A., R.R.A., Z.H.A.K., T.J.A., A.S.A., H.S.A.D., A.F.A., F.N.A. and A.A.A. significantly contributed to this systematic review. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-medicina-59-00642"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Yellepeddi</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Sherwin</surname><given-names>C.M.T.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Inhaled Antimicrobials</article-title><source>Clin. Pharmacokinet.</source><year>2015</year><volume>54</volume><fpage>473</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0250-x</pub-id><pub-id pub-id-type="pmid">25735634</pub-id></element-citation></ref><ref id="B2-medicina-59-00642"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolovich</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Dhand</surname><given-names>R.</given-names></name></person-group><article-title>Aerosol drug delivery: Developments in device design and clinical use</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>1032</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60926-9</pub-id><pub-id pub-id-type="pmid">21036392</pub-id></element-citation></ref><ref id="B3-medicina-59-00642"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>A.J.</given-names></name></person-group><article-title>Emerging trends in inhaled drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>157</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.006</pub-id><pub-id pub-id-type="pmid">32663488</pub-id><pub-id pub-id-type="pmcid">PMC7354278</pub-id></element-citation></ref><ref id="B4-medicina-59-00642"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>P.</given-names></name><name name-style="western"><surname>B&#228;ckman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cipolla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daviskas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Disse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Entcheva-Dimitrov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonda</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Inhaled Medicines: Past, Present, and Future</article-title><source>Pharmacol. Rev.</source><year>2022</year><volume>74</volume><fpage>48</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1124/pharmrev.120.000108</pub-id><pub-id pub-id-type="pmid">34987088</pub-id></element-citation></ref><ref id="B5-medicina-59-00642"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>S.P.</given-names></name></person-group><article-title>Drug delivery to the lungs: Challenges and opportunities</article-title><source>Ther. Deliv.</source><year>2017</year><volume>8</volume><fpage>647</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.4155/tde-2017-0037</pub-id><pub-id pub-id-type="pmid">28730933</pub-id></element-citation></ref><ref id="B6-medicina-59-00642"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garcia-Contreras</surname><given-names>L.</given-names></name></person-group><article-title>Inhalation drug delivery devices: Technology update</article-title><source>Med. Devices</source><year>2015</year><volume>8</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/MDER.S48888</pub-id><pub-id pub-id-type="pmcid">PMC4334339</pub-id><pub-id pub-id-type="pmid">25709510</pub-id></element-citation></ref><ref id="B7-medicina-59-00642"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heyder</surname><given-names>J.</given-names></name></person-group><article-title>Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery</article-title><source>Proc. Am. Thorac. Soc.</source><year>2004</year><volume>1</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1513/pats.200409-046TA</pub-id><pub-id pub-id-type="pmid">16113452</pub-id></element-citation></ref><ref id="B8-medicina-59-00642"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K.H.P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>A.W.</given-names></name></person-group><article-title>A Population Pharmacokinetic Analysis of Zanamivir in Subjects with Experimental and Naturally Occurring Influenza: Effects of Formulation and Route of Administration</article-title><source>J. Clin. Pharmacol.</source><year>2000</year><volume>40</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1177/00912700022008900</pub-id><pub-id pub-id-type="pmid">10709152</pub-id></element-citation></ref><ref id="B9-medicina-59-00642"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groneberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>U.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>A.</given-names></name></person-group><article-title>Fundamentals of pulmonary drug delivery</article-title><source>Respir. Med.</source><year>2003</year><volume>97</volume><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1053/rmed.2002.1457</pub-id><pub-id pub-id-type="pmid">12693798</pub-id></element-citation></ref><ref id="B10-medicina-59-00642"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishizuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Toyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshiba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Furuie</surname><given-names>H.</given-names></name></person-group><article-title>Intrapulmonary Distribution and Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Inhaled Administration of Its Prodrug, Laninamivir Octanoate, in Healthy Volunteers</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>3873</fpage><lpage>3878</lpage><pub-id pub-id-type="doi">10.1128/AAC.06456-11</pub-id><pub-id pub-id-type="pmid">22526307</pub-id><pub-id pub-id-type="pmcid">PMC3393442</pub-id></element-citation></ref><ref id="B11-medicina-59-00642"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Labiris</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Dolovich</surname><given-names>M.B.</given-names></name></person-group><article-title>Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications</article-title><source>Br. J. Clin. Pharmacol.</source><year>2003</year><volume>56</volume><fpage>600</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01893.x</pub-id><pub-id pub-id-type="pmid">14616419</pub-id><pub-id pub-id-type="pmcid">PMC1884297</pub-id></element-citation></ref><ref id="B12-medicina-59-00642"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia-Contreras</surname><given-names>L.</given-names></name></person-group><article-title>Mechanisms of absorption and elimination of drugs administered by inhalation</article-title><source>Ther. Deliv.</source><year>2013</year><volume>4</volume><fpage>1027</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.4155/tde.13.67</pub-id><pub-id pub-id-type="pmid">23919477</pub-id></element-citation></ref><ref id="B13-medicina-59-00642"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Weller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Piscitelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peppercorn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ng-Cashin</surname><given-names>J.</given-names></name></person-group><source>Safety, Tolerability and Pharmacokinetics of Orally Inhaled Zanamivir: A Randomized Study Comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in Healthy Adults</source><publisher-name>SAGE Publications</publisher-name><publisher-loc>London, UK</publisher-loc><year>2013</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3851/IMP2631</pub-id><pub-id pub-id-type="pmid">23696221</pub-id></element-citation></ref><ref id="B14-medicina-59-00642"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akbal-Dagistan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Culha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Erturk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Basarir</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Sancar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yildiz-Pekoz</surname><given-names>A.</given-names></name></person-group><article-title>Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment</article-title><source>J. Pharm. Sci.</source><year>2022</year><volume>111</volume><fpage>2652</fpage><lpage>2661</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.06.004</pub-id><pub-id pub-id-type="pmid">35691607</pub-id><pub-id pub-id-type="pmcid">PMC9181835</pub-id></element-citation></ref><ref id="B15-medicina-59-00642"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodier-Montagutelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mayor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vecellio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Respaud</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heuz&#233;-Vourc&#8217;h</surname><given-names>N.</given-names></name></person-group><article-title>Designing inhaled protein therapeutics for topical lung delivery: What are the next steps?</article-title><source>Expert Opin. Drug Deliv.</source><year>2018</year><volume>15</volume><fpage>729</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1080/17425247.2018.1503251</pub-id><pub-id pub-id-type="pmid">30025210</pub-id></element-citation></ref><ref id="B16-medicina-59-00642"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seow</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Man</surname><given-names>R.C.H.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus</article-title><source>Adv. Ther.</source><year>2021</year><volume>4</volume><fpage>2100059</fpage><pub-id pub-id-type="doi">10.1002/adtp.202100059</pub-id></element-citation></ref><ref id="B17-medicina-59-00642"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdellatif</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Tawfeek</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Abdelfattah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>G.E.-S.</given-names></name><name name-style="western"><surname>Hetta</surname><given-names>H.F.</given-names></name></person-group><article-title>Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>63</volume><fpage>102435</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102435</pub-id><pub-id pub-id-type="pmid">33643448</pub-id><pub-id pub-id-type="pmcid">PMC7894098</pub-id></element-citation></ref><ref id="B18-medicina-59-00642"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cass</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Efthymiopoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bye</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers</article-title><source>Clin. Pharmacokinet.</source><year>1999</year><volume>36</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.2165/00003088-199936001-00001</pub-id><pub-id pub-id-type="pmid">10429835</pub-id></element-citation></ref><ref id="B19-medicina-59-00642"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cass</surname><given-names>L.M.R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pickford</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fayinka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Bye</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy Volunteers</article-title><source>Clin. Pharmacokinet.</source><year>1999</year><volume>36</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.2165/00003088-199936001-00003</pub-id><pub-id pub-id-type="pmid">10429837</pub-id></element-citation></ref><ref id="B20-medicina-59-00642"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishizuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoshiba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoshihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H.</given-names></name></person-group><article-title>Assessment of the Effects of Renal Impairment on the Pharmacokinetic Profile of Laninamivir, a Novel Neuraminidase Inhibitor, After a Single Inhaled Dose of Its Prodrug, CS-8958</article-title><source>J. Clin. Pharmacol.</source><year>2011</year><volume>51</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1177/0091270010361914</pub-id><pub-id pub-id-type="pmid">20197485</pub-id></element-citation></ref><ref id="B21-medicina-59-00642"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishizuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoshiba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoshihara</surname><given-names>K.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Laninamivir, a Novel Long-Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS-8958, in Healthy Male Volunteers</article-title><source>J. Clin. Pharmacol.</source><year>2010</year><volume>50</volume><fpage>1319</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1177/0091270009356297</pub-id><pub-id pub-id-type="pmid">20145259</pub-id></element-citation></ref><ref id="B22-medicina-59-00642"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshiba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>H.</given-names></name></person-group><article-title>Pharmacokinetics of laninamivir after a single administration of its prodrug, laninamivir octanoate, a long-acting neuraminidase inhibitor, using an easy-to-use inhaler in healthy volunteers</article-title><source>J. Bioequiv. Availab.</source><year>2011</year><volume>3</volume><fpage>001</fpage><lpage>004</lpage><pub-id pub-id-type="doi">10.4172/jbb.1000048</pub-id></element-citation></ref><ref id="B23-medicina-59-00642"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>Y.</given-names></name></person-group><article-title>Population Pharmacokinetics of Laninamivir and Its Prodrug Laninamivir Octanoate in Healthy Subjects and in Adult and Pediatric Patients with Influenza Virus Infection</article-title><source>Drug Metab. Pharmacokinet.</source><year>2013</year><volume>28</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-12-RG-115</pub-id><pub-id pub-id-type="pmid">23574886</pub-id></element-citation></ref><ref id="B24-medicina-59-00642"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couroux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brkovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vittitow</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Israel</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Pamidi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>M.</given-names></name></person-group><article-title>A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin</article-title><source>Clin. Transl. Sci.</source><year>2022</year><volume>15</volume><fpage>2159</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1111/cts.13350</pub-id><pub-id pub-id-type="pmid">35677972</pub-id><pub-id pub-id-type="pmcid">PMC9468560</pub-id></element-citation></ref><ref id="B25-medicina-59-00642"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumont</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ioannou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Billiard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Den Berg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chandrasekaran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Lahiry</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e02267-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.02267-19</pub-id><pub-id pub-id-type="pmid">32071044</pub-id><pub-id pub-id-type="pmcid">PMC7179635</pub-id></element-citation></ref><ref id="B26-medicina-59-00642"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atmar</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Quarles</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Couch</surname><given-names>R.B.</given-names></name></person-group><article-title>Safety and pharmacokinetics of rimantadine small-particle aerosol</article-title><source>Antimicrob. Agents Chemother.</source><year>1990</year><volume>34</volume><fpage>2228</fpage><lpage>2233</lpage><pub-id pub-id-type="doi">10.1128/AAC.34.11.2228</pub-id><pub-id pub-id-type="pmid">2073113</pub-id><pub-id pub-id-type="pmcid">PMC172027</pub-id></element-citation></ref><ref id="B27-medicina-59-00642"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Jefferson</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Taber</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>B.E.</given-names></name></person-group><article-title>High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection</article-title><source>J. Pediatr.</source><year>1990</year><volume>117</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(05)80554-2</pub-id><pub-id pub-id-type="pmid">2380833</pub-id></element-citation></ref><ref id="B28-medicina-59-00642"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linn</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Shamoo</surname><given-names>D.A.</given-names></name></person-group><article-title>Exposures of Health-Care Workers to Ribavirin Aerosol: A Pharmacokinetic Study</article-title><source>Arch. Environ. Health Int. J.</source><year>1995</year><volume>50</volume><fpage>445</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1080/00039896.1995.9935981</pub-id><pub-id pub-id-type="pmid">8572723</pub-id></element-citation></ref><ref id="B29-medicina-59-00642"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furuie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>H.</given-names></name></person-group><article-title>Safety and Pharmacokinetics of Nebulized Laninamivir Octanoate, A Long Acting Neuraminidase Inhibitor, In Healthy Subjects</article-title><source>Clin. Ther.</source><year>2017</year><volume>39</volume><fpage>e25</fpage><lpage>e26</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2017.05.078</pub-id></element-citation></ref><ref id="B30-medicina-59-00642"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Rosolowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blumer</surname><given-names>J.L.</given-names></name></person-group><article-title>Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children</article-title><source>Curr. Ther. Res.</source><year>2000</year><volume>61</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S0011-393X(00)88495-7</pub-id></element-citation></ref><ref id="B31-medicina-59-00642"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shelton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lovern</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ng-Cashin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gauvin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rodvold</surname><given-names>K.A.</given-names></name></person-group><article-title>Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following Intravenous or Oral Inhaled Administration to Healthy Adult Subjects</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>5178</fpage><lpage>5184</lpage><pub-id pub-id-type="doi">10.1128/AAC.00703-11</pub-id><pub-id pub-id-type="pmid">21896909</pub-id><pub-id pub-id-type="pmcid">PMC3195002</pub-id></element-citation></ref><ref id="B32-medicina-59-00642"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>R.-H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.-X.</given-names></name></person-group><article-title>A method to determine pharmacokinetic parameters based on andante constant-rate intravenous infusion</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>13279</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-13437-6</pub-id><pub-id pub-id-type="pmid">29038495</pub-id><pub-id pub-id-type="pmcid">PMC5643313</pub-id></element-citation></ref><ref id="B33-medicina-59-00642"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berkenfeld</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lamprecht</surname><given-names>A.</given-names></name><name name-style="western"><surname>McConville</surname><given-names>J.T.</given-names></name></person-group><article-title>Devices for Dry Powder Drug Delivery to the Lung</article-title><source>AAPS PharmSciTech</source><year>2015</year><volume>16</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1208/s12249-015-0317-x</pub-id><pub-id pub-id-type="pmid">25964142</pub-id><pub-id pub-id-type="pmcid">PMC4444630</pub-id></element-citation></ref><ref id="B34-medicina-59-00642"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>A.</given-names></name></person-group><article-title>Emerging respiratory infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella</article-title><source>Semin. Diagn. Pathol.</source><year>2019</year><volume>36</volume><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1053/j.semdp.2019.04.006</pub-id><pub-id pub-id-type="pmid">31054790</pub-id><pub-id pub-id-type="pmcid">PMC7125557</pub-id></element-citation></ref><ref id="B35-medicina-59-00642"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Cadarette</surname><given-names>D.</given-names></name></person-group><article-title>Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>549</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00549</pub-id><pub-id pub-id-type="pmid">30984169</pub-id><pub-id pub-id-type="pmcid">PMC6447676</pub-id></element-citation></ref><ref id="B36-medicina-59-00642"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayville</surname><given-names>L.R.</given-names></name></person-group><article-title>Influenza update: A review of currently available vaccines</article-title><source>P T A Peer-Rev. J. Formul. Manag.</source><year>2011</year><volume>36</volume><fpage>659</fpage><lpage>684</lpage><pub-id pub-id-type="pmcid">PMC3278149</pub-id><pub-id pub-id-type="pmid">22346299</pub-id></element-citation></ref><ref id="B37-medicina-59-00642"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shun-Shin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harnden</surname><given-names>A.</given-names></name></person-group><article-title>Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)</article-title><source>Cochrane Database Syst. Rev.</source><year>2012</year><volume>2012</volume><fpage>CD002744</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD002744.pub4</pub-id><pub-id pub-id-type="pmid">22513907</pub-id><pub-id pub-id-type="pmcid">PMC6599832</pub-id></element-citation></ref><ref id="B38-medicina-59-00642"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mifsud</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>Antivirals targeting the polymerase complex of influenza viruses</article-title><source>Antivir. Res.</source><year>2019</year><volume>169</volume><fpage>104545</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104545</pub-id><pub-id pub-id-type="pmid">31247246</pub-id></element-citation></ref><ref id="B39-medicina-59-00642"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#346;wierczy&#324;ska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirowska-Guzel</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pindelska</surname><given-names>E.</given-names></name></person-group><article-title>Antiviral Drugs in Influenza</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>3018</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19053018</pub-id><pub-id pub-id-type="pmid">35270708</pub-id><pub-id pub-id-type="pmcid">PMC8910682</pub-id></element-citation></ref><ref id="B40-medicina-59-00642"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chairat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tarning</surname><given-names>J.</given-names></name><name name-style="western"><surname>White</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Lindegardh</surname><given-names>N.</given-names></name></person-group><article-title>Pharmacokinetic Properties ofAnti-Influenza Neuraminidase Inhibitors</article-title><source>J. Clin. Pharmacol.</source><year>2013</year><volume>53</volume><fpage>119</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1177/0091270012440280</pub-id><pub-id pub-id-type="pmid">23436258</pub-id></element-citation></ref><ref id="B41-medicina-59-00642"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hilgenfeld</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Recent Advances in Neuraminidase Inhibitor Development as Anti-influenza Drugs</article-title><source>Chemmedchem</source><year>2012</year><volume>7</volume><fpage>1527</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201200155</pub-id><pub-id pub-id-type="pmid">22807317</pub-id></element-citation></ref><ref id="B42-medicina-59-00642"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>M.</given-names></name></person-group><article-title>Laninamivir and its Prodrug, <bold>CS-8958:</bold> Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza</article-title><source>Antivir. Chem. Chemother.</source><year>2010</year><volume>21</volume><fpage>71</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.3851/IMP1688</pub-id><pub-id pub-id-type="pmid">21107016</pub-id></element-citation></ref><ref id="B43-medicina-59-00642"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sriwilaijaroen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vavricka</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Kiyota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y.</given-names></name></person-group><article-title>Influenza A Virus Neuraminidase Inhibitors</article-title><source>Glycovirology: Methods and Protocols</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2022</year><fpage>321</fpage><lpage>353</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-2635-1_21</pub-id><pub-id pub-id-type="pmid">36175642</pub-id></element-citation></ref><ref id="B44-medicina-59-00642"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galvin</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Haw</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Nutsford</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>M.</given-names></name></person-group><article-title>Drug resistance in influenza A virus: The epidemiology and management</article-title><source>Infect. Drug Resist.</source><year>2017</year><volume>10</volume><fpage>121</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.2147/IDR.S105473</pub-id><pub-id pub-id-type="pmid">28458567</pub-id><pub-id pub-id-type="pmcid">PMC5404498</pub-id></element-citation></ref><ref id="B45-medicina-59-00642"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaraket</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>R.</given-names></name></person-group><article-title>Japanese Surveillance Systems and Treatment for Influenza</article-title><source>Curr. Treat. Options Infect. Dis.</source><year>2016</year><volume>8</volume><fpage>311</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1007/s40506-016-0085-5</pub-id><pub-id pub-id-type="pmid">28035195</pub-id><pub-id pub-id-type="pmcid">PMC5155020</pub-id></element-citation></ref><ref id="B46-medicina-59-00642"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavia</surname><given-names>A.T.</given-names></name></person-group><article-title>Viral Infections of the Lower Respiratory Tract: Old Viruses, New Viruses, and the Role of Diagnosis</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><issue>(Suppl. S4)</issue><fpage>S284</fpage><lpage>S289</lpage><pub-id pub-id-type="doi">10.1093/cid/cir043</pub-id><pub-id pub-id-type="pmid">21460286</pub-id><pub-id pub-id-type="pmcid">PMC3106235</pub-id></element-citation></ref><ref id="B47-medicina-59-00642"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azzari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baraldi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bonanni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bozzola</surname><given-names>E.</given-names></name><name name-style="western"><surname>Coscia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lanari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manzoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sandri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lisi</surname><given-names>G.C.</given-names></name><etal/></person-group><article-title>Epidemiology and prevention of respiratory syncytial virus infections in children in Italy</article-title><source>Ital. J. Pediatr.</source><year>2021</year><volume>47</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.1186/s13052-021-01148-8</pub-id><pub-id pub-id-type="pmid">34600591</pub-id><pub-id pub-id-type="pmcid">PMC8487331</pub-id></element-citation></ref><ref id="B48-medicina-59-00642"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>G.</given-names></name><name name-style="western"><surname>Landgrave</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.</given-names></name></person-group><article-title>Respiratory syncytial virus: Current and emerging treatment options</article-title><source>Clin. Outcomes Res.</source><year>2014</year><volume>6</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.2147/CEOR.S60710</pub-id><pub-id pub-id-type="pmcid">PMC4008286</pub-id><pub-id pub-id-type="pmid">24812523</pub-id></element-citation></ref><ref id="B49-medicina-59-00642"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Welliver</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simoes</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Stutman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Dyke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Groothuis</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Arrobio</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double-blind, multicenter, placebo-controlled trial</article-title><source>J. Pediatr.</source><year>1994</year><volume>125</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(94)70139-3</pub-id><pub-id pub-id-type="pmid">8021762</pub-id></element-citation></ref><ref id="B50-medicina-59-00642"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name></person-group><article-title>Antiviral therapy of influenza</article-title><source>Semin. Pediatr. Infect. Dis.</source><year>2002</year><volume>13</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1053/spid.2002.122999</pub-id><pub-id pub-id-type="pmid">12122950</pub-id></element-citation></ref><ref id="B51-medicina-59-00642"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venisse</surname><given-names>N.</given-names></name><name name-style="western"><surname>Peytavin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bouchet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gagnieu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Garraffo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guilhaumou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Solas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monitoring</surname><given-names>S.T.D.</given-names></name></person-group><article-title>ANRS-AC43 Clinical Pharmacology Committee Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection</article-title><source>Antivir. Res.</source><year>2020</year><volume>181</volume><fpage>104866</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104866</pub-id><pub-id pub-id-type="pmid">32659293</pub-id><pub-id pub-id-type="pmcid">PMC7351053</pub-id></element-citation></ref><ref id="B52-medicina-59-00642"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nystr&#246;m</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waldenstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>K.-W.</given-names></name><name name-style="western"><surname>Lagging</surname><given-names>M.</given-names></name></person-group><article-title>Ribavirin: Pharmacology, multiple modes of action and possible future perspectives</article-title><source>Future Virol.</source><year>2019</year><volume>14</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.2217/fvl-2018-0166</pub-id></element-citation></ref><ref id="B53-medicina-59-00642"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glue</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schenker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Zambas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salfi</surname><given-names>M.</given-names></name></person-group><article-title>The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease</article-title><source>Br. J. Clin. Pharmacol.</source><year>2000</year><volume>49</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2000.00186.x</pub-id><pub-id pub-id-type="pmid">10792198</pub-id><pub-id pub-id-type="pmcid">PMC2014952</pub-id></element-citation></ref><ref id="B54-medicina-59-00642"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nainwal</surname><given-names>N.</given-names></name></person-group><article-title>Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities</article-title><source>Pulm. Pharmacol. Ther.</source><year>2022</year><volume>77</volume><fpage>102170</fpage><pub-id pub-id-type="doi">10.1016/j.pupt.2022.102170</pub-id><pub-id pub-id-type="pmid">36240985</pub-id><pub-id pub-id-type="pmcid">PMC9554202</pub-id></element-citation></ref><ref id="B55-medicina-59-00642"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Restrepo</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Keyt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>L.F.</given-names></name></person-group><article-title>Aerosolized Antibiotics</article-title><source>Respir. Care</source><year>2015</year><volume>60</volume><fpage>762</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.4187/respcare.04208</pub-id><pub-id pub-id-type="pmid">26070573</pub-id></element-citation></ref><ref id="B56-medicina-59-00642"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Zylidnikov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iljenko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Padolka</surname><given-names>Y.</given-names></name></person-group><article-title>Comparative therapeutic effect of aerosolized and oral rimantadine HC1 in experimental human influenza A virus infection</article-title><source>Antivir. Res.</source><year>1982</year><volume>2</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(82)90016-X</pub-id><pub-id pub-id-type="pmid">7137990</pub-id></element-citation></ref><ref id="B57-medicina-59-00642"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Minocha</surname><given-names>A.</given-names></name><name name-style="western"><surname>A Spyker</surname><given-names>D.</given-names></name><name name-style="western"><surname>E Hoffman</surname><given-names>H.</given-names></name></person-group><article-title>Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults</article-title><source>Antimicrob. Agents Chemother.</source><year>1985</year><volume>28</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1128/AAC.28.2.216</pub-id><pub-id pub-id-type="pmid">3834831</pub-id><pub-id pub-id-type="pmcid">PMC180222</pub-id></element-citation></ref><ref id="B58-medicina-59-00642"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velkov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abdul Rahim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.T.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>85</volume><fpage>65</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.11.004</pub-id><pub-id pub-id-type="pmid">25446140</pub-id><pub-id pub-id-type="pmcid">PMC4429008</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="medicina-59-00642-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flow chart of included studies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-59-00642-g001.jpg"/></fig><table-wrap position="float" id="medicina-59-00642-t001" orientation="portrait"><object-id pub-id-type="pii">medicina-59-00642-t001_Table 1</object-id><label>Table 1</label><caption><p>Overview of final search strategy with MeSH terms and text words for each of the four domains (pharmacokinetics, antivirals, characteristics of patient, and type of population).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmacokinetics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antivirals</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics of Patient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Population</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MeSH terms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MeSH terms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MeSH terms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MeSH terms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical pharmacokinetics (MeSH)<break/>Clinical pharmacokinetics (subheading)<break/>Drug monitoring (subheading)<break/>Pharmacokinetic analysis (subheading)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral agents (MeSH)<break/>Antimicrobial agents (MeSH)<break/>Inhaled antiviral agents (MeSH)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy volunteers<break/>Patients with viral infection<break/>Critically ill</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pediatric patients (MeSH)<break/>Adolescents (MeSH)<break/>Adults (MeSH)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Title/Abstract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Title/Abstract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Title/Abstract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Title/Abstract</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacokinetic, pharmacodynamic, target attainment, area under curve, maximum plasma concentration, drug monitoring, drug deposition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">See electronic and <xref rid="app1-medicina-59-00642" ref-type="app">supplementary file</xref></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza, healthy, subjects, volunteers, renal impairment, critically ill, ICU patients, PICU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children, workers, youth, males, females, elderly, adults, babies</td></tr></tbody></table><table-wrap-foot><fn><p>Keywords within each domain were combined with OR; all domains were combined with AND, as shown in <xref rid="app1-medicina-59-00642" ref-type="app">Supplementary File</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="medicina-59-00642-t002" orientation="portrait"><object-id pub-id-type="pii">medicina-59-00642-t002_Table 2</object-id><label>Table 2</label><caption><p>Main characteristics of studies on inhaled antiviral drugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Research Objectives</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome Measures</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Spray Device</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Structure</th></tr></thead><tbody><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Zenamivir</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cass et al., 1999<break/>[<xref rid="B18-medicina-59-00642" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To assess the clinical PKs and safety of Zanamivir.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, t<sub>1/2</sub>,<break/>Cl, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nebulizer/dry powder inhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weller et al., 2013<break/>[<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To evaluate preliminary PKs and safety data to support the use of Zanamivir via Rotahaler/Rotacap. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub>, t<sub>1/2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rotadisk/Diskhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed-effect models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cass et al., 1999<break/>[<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To determine the sites of Zanamivir deposition in the respiratory tract and the PKs of Zanamivir via Diskhaler device and a prototype device.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, t<sub>1/2</sub>, Cl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diskhaler/prototype device</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peng et al., 2000<break/>[<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To assess the population PKs of Zenamivir in participants with experimental and naturally occurring influenza.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cl, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">201</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal and inhaled powder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed-effect models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peng et al., 2000<break/>[<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To examine the PKs, safety, and tolerability of Zanamivir in pediatric patients.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub>, t<sub>1/2</sub>, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nebulizer and Diskhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartment model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shelton et al., 2011<break/>[<xref rid="B31-medicina-59-00642" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To evaluate serum as well as pulmonary PKs following IV and oral inhaled administration.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-randomized study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub>, t<sub>1/2</sub>, Cl, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diskhaler and Rotahaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Laninamivir</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ishizuka et al., 2011<break/>[<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To assess the safety and PKs of Laninamivir after administration of its prodrug, CS-8958.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub>, t<sub>1/2</sub>, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flowcaps dry powder inhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartment model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ishizuka et al., 2010<break/>[<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To evaluate its safety, tolerability, and PKs after inhaled administration of its prodrug, CS-8958.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub>, t<sub>1/2</sub>, Cl, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flowcaps dry powder inhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yoshiba et al., 2011<break/>[<xref rid="B22-medicina-59-00642" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To measure the PK parameters of Laninamivir using a new easy-to-use inhaler.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub>, t<sub>1/2,</sub> Cl, V<sub>d</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flow powder inhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ishizuka et al., 2012<break/>[<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To determine the intrapulmonary PKs of LO and Laninamivir.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open-label study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T <sub>max</sub>, T<sub>1/2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dry powder inhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toyama et al., 2017<break/>[<xref rid="B29-medicina-59-00642" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To evaluate the safety and PKs of Nebulized Laninamivir Octanoate.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open-label study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T<sub>1/2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reusable nebulizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yoshihara et al., 2013<break/>[<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To study the population PKs of LO and Laninamivir in healthy subjects, and adult and pediatric patients with influenza virus infection from eight clinical studies, and to evaluate covariate effects on PKs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>1/2</sub>, Cl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">175</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prototype and commercial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One- and two-compartmental models</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Ribavirin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Couroux et al., 2022<break/>[<xref rid="B24-medicina-59-00642" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To assess the safety and PKs of four, single-dose regimens of Ribavirin aerosol.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, t<sub>1/2,</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Air-jet nebulizer </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Englund et al., 1990<break/>[<xref rid="B27-medicina-59-00642" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To evaluate the safety of high-dose, short-duration Ribavirin aerosol therapy in pediatric patients with suspected RSV infection.<break/>To evaluate the drug concentrations in blood and respiratory secretions and antiviral effects.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preliminary study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, t<sub>1/2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aerosol nebulizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linn et al., 1995<break/>[<xref rid="B28-medicina-59-00642" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To evaluate exposure variables including aerosol concentration, duration of exposure, aerosol size range, and exposed participants&#8217; ventilation rates.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preliminary study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, t<sub>1/2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aerosol nebulizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dumont et al., 2020<break/>[<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To assess the efficient delivery of Ribavirin using the particle replication in non-wetting templates (PRINT) technology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub>, AUC, T<sub>max</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rotahaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Rimantadine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atmar et al., 1990<break/>[<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To assess the safety and PKs of rimantadine in healthy adults and adults with acute influenza virus infection.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC, t<sub>1/2</sub>, Cl, V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Collison nebulizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-compartmental model</td></tr></tbody></table><table-wrap-foot><fn><p>RCT = randomized controlled trial, C<sub>max</sub> = maximum concentration, AUC = area under curve, T<sub>1/2</sub> = half-life, V<sub>d</sub> = volume of distribution, Cl = clearance, PKs = pharmacokinetics, LO = Laninamivir Octanoate, T<sub>max</sub> = time to peak drug concentration.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="medicina-59-00642-t003" orientation="portrait"><object-id pub-id-type="pii">medicina-59-00642-t003_Table 3</object-id><label>Table 3</label><caption><p>Pharmacokinetic parameters of inhaled antiviral drugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Drug/Study</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dosing Practice</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pharmacokinetic Parameters</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T<sub>1/2</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V<sub>d</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cl</th></tr></thead><tbody><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Zenamivir</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cass et al., 1999<break/>[<xref rid="B18-medicina-59-00642" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single and multiple doses of 8 and 16 mg six times daily for 5 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>63&#8211;139 &#181;g/L<break/><bold>Dry powder inhaler:</bold><break/>Cmax: 39&#8211;54 &#181;g/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>2.21 h<break/><bold>Dry powder inhaler:</bold><break/>3.56 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer</bold><break/>425 &#181;g.h/L<break/><bold>Dry powder inhaler</bold><break/>160 &#181;g.h/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weller et al., 2013<break/>[<xref rid="B13-medicina-59-00642" ref-type="bibr">13</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A dose of 10 mg via oral inhalation every 12 h for 5 days using Rotadisk/Diskhaler<break/>A dose of 10 mg via oral inhalation every 12 h for 5 days using Rotacap/Rotahaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler:</bold><break/>32 ng/mL<break/><bold>Rotahaler:</bold><break/>37 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler:</bold><break/>3 h<break/><bold>Rotahaler:</bold><break/>3.2 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler:</bold><break/>133 ng.h/mL<break/><bold>Rotahaler:</bold><break/>157 ng.h/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler:</bold><break/>54 L/h<break/><bold>Rotahaler:</bold><break/>49 L/h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cass et al., 1999<break/>[<xref rid="B19-medicina-59-00642" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A dose of 10 mg using Diskhaler<break/>A dose of 10 mg using prototype device</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler:</bold><break/>34 &#181;g/L<break/><bold>Prototype device:</bold><break/>30 &#181;g/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler:</bold><break/>2.5 h<break/><bold>Prototype device:</bold><break/>3.0 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler</bold><break/>184 &#181;g.h/L<break/><bold>Rotahaler</bold><break/>190 &#181;g.h/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diskhaler</bold><break/>54.3 L/h<break/><bold>Rotahaler</bold><break/>52.6 L/h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peng et al., 2000<break/>[<xref rid="B8-medicina-59-00642" ref-type="bibr">8</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo/Zanamivir twice daily for 5 days either intranasally (10 mg) or orally inhaled (6.4 mg)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Intranasal:</bold><break/>296 L<break/><bold>Inhaled powder:</bold><break/>161 L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Intranasal:</bold><break/>Cl: 74.1 L/h<break/><bold>Inhaled powder:</bold><break/>Cl: 40 L/h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peng et al., 2000<break/>[<xref rid="B30-medicina-59-00642" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A dose of 10 mg inhaled by nebulizer<break/>A dose of 10 mg inhaled by Diskhaler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>47 &#181;g/L<break/><bold>Diskhaler:</bold><break/>40&#8211;47 &#181;g/L </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>1.9 h<break/><bold>Diskhaler:</bold><break/>2 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>184 &#181;g. h/L<break/><bold>Diskhaler:</bold><break/>167&#8211;192 &#181;g.h/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>16.9 L<break/><bold>Diskhaler:</bold><break/>3.5&#8211;6.9 L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Nebulizer:</bold><break/>54.3 L/h<break/><bold>Diskhaler:</bold><break/>52.1&#8211;60 L/h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shelton et al., 2011<break/>[<xref rid="B31-medicina-59-00642" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 mg q12h for two doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.2 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">175 ng.h/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Laninamivir</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ishizuka et al., 2011<break/>[<xref rid="B20-medicina-59-00642" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A single inhaled dose of 20 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>57.4&#8211;74.3 ng/mL<break/><bold>Laninamivir:</bold><break/>14.5&#8211;29.9 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>2.3&#8211;5.3 h<break/><bold>Laninamivir:</bold><break/>53.2&#8211;57 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>291&#8211;401<break/><bold>Laninamivir:</bold><break/>426&#8211;2223 ng.h/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>6.5&#8211;26 mL/min<break/><bold>Laninamivir:</bold><break/>12.7&#8211;65 mL/min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ishizuka et al.,<break/>2010<break/>[<xref rid="B21-medicina-59-00642" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doses of CS-8958 of 5 mg&#8211;120 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>12.8&#8211;433 ng/mL<break/><bold>Laninamivir:</bold><break/>2.6&#8211;66 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>1.7&#8211;10.7 h<break/><bold>Laninamivir:</bold><break/>5.7&#8211;80.8 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>45.3&#8211;1567<break/><bold>Laninamivir:</bold><break/>19.9&#8211;2059</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>193&#8211;956 L<break/><bold>Laninamivir:</bold><break/>Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>CS-8958:</bold><break/>35&#8211;61 mL/min<break/><bold>Laninamivir:</bold><break/>90&#8211;576 mL/min</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yoshiba et al., 2011 [<xref rid="B22-medicina-59-00642" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doses of 20 mg and 40 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>19&#8211;38.3 ng/mL<break/><bold>LO:</bold><break/>145&#8211;336 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>66.6&#8211;74.4 h<break/><bold>LO:</bold><break/>1.79&#8211;2.70 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>558&#8211;1080 ng.h/mL<break/><bold>LO:</bold><break/>440&#8211;1018 ng.h/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>Not stated<break/><bold>LO:</bold><break/>121&#8211;160 L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>84.9&#8211;106.9 mL/min<break/><bold>LO:</bold><break/>34.3&#8211;35.9 mL/min</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ishizuka et al., 2012<break/>[<xref rid="B10-medicina-59-00642" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A single inhaled dose of 40 mg of LO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>0.025&#8211;152.3 &#181;g/mL<break/><bold>LO:</bold><break/>0.162&#8211;2085 &#181;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>45.7 h<break/><bold>LO:</bold><break/>2.6&#8211;89.9 h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>0.826&#8211;17,271 &#181;g/mL<break/><bold>LO:</bold><break/>0.705&#8211;31942</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toyama et al., 2017<break/>[<xref rid="B29-medicina-59-00642" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A single dose of 40~320 mg of LO was inhaled</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>58.3&#8211;165.8 h<break/><bold>LO:</bold><break/>1.8&#8211;55.1 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yoshihara et al., 2013<break/>[<xref rid="B23-medicina-59-00642" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Group 1:</bold> 5, 10, 20, 40 mg (single dose)<break/><bold>Group 2:</bold> 20, 40 mg (BID, 3 days)<break/><bold>Group 3:</bold> 40 mg (single dose: young and elderly); 20 mg (QID, 2 days: elderly only)<break/><bold>Group 4:</bold> 20 mg (single dose)<break/><bold>Group 5:</bold> 80, 120 mg (single dose)<break/><bold>Group 6</bold> 40 mg (single dose)<break/><bold>Group 7:</bold> 20, 40 mg (single dose); 20 mg (QID, 2 days)<break/><bold>Group 8:</bold> 40 mg (single dose)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>4 h<break/><bold>LO:</bold><break/>2 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Laninamivir:</bold><break/>5.21 h/L<break/><bold>LO:</bold><break/>64.8 h/L</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Ribavirin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Couroux et al., 2022<break/>[<xref rid="B24-medicina-59-00642" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort 1:</bold> 50 mg/mL Ribavirin/placebo (10 mL total volume)<break/><bold>Cohort 2:</bold> 50 mg/mL Ribavirin/placebo (20 mL total volume)<break/><bold>Cohort 3:</bold> 100 mg/mL Ribavirin/placebo (10 mL total volume)<break/><bold>Cohort 4:</bold> 100 mg/mL Ribavirin/placebo (20 mL total volume)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort 1:</bold><break/>0.63 &#181;g/mL<break/><bold>Cohort 2:</bold><break/>1.07 &#181;g/mL<break/><bold>Cohort 3:</bold><break/>0.95 &#181;g/mL<break/><bold>Cohort 4:</bold><break/>1.64 &#181;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort 1:</bold><break/>1 h<break/><bold>Cohort 2:</bold><break/>1.75 h<break/><bold>Cohort 3:</bold><break/>1.5 h<break/><bold>Cohort 4:</bold><break/>2.0 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort 1:</bold><break/>4.90 &#181;g/mL<break/><bold>Cohort 2:</bold><break/>10.55 &#181;g/mL<break/><bold>Cohort 3:</bold><break/>9.27 &#181;g/mL<break/><bold>Cohort 4:</bold><break/>15.55 &#181;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Englund et al., 1990<break/>[<xref rid="B27-medicina-59-00642" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A dose of 60 mg/mL for 2 h periods TID for up to 5 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1725&#8211;2179 pmol/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linn et al., 1995<break/>[<xref rid="B28-medicina-59-00642" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>High exposure group</bold><break/>A dose of 30 mg QID for 4 days<break/><bold>Low exposure group</bold><break/>A dose of 3 mg QID for 4 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89 pmol/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37&#8211;39 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dumont et al., 2020 [<xref rid="B25-medicina-59-00642" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort A</bold><break/>Single dose of 60 mg and 120 mg followed by 30 mg BID for 14 days<break/><bold>Cohort B</bold><break/>60 mg BID for 14 consecutive days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort A:</bold><break/>143&#8211;508 ng/mL<break/><bold>Cohort B:</bold><break/>189&#8211;285 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort A:</bold><break/>0.5&#8211;0.625 h<break/><bold>Cohort B:</bold><break/>0.5&#8211;0.633 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cohort A:</bold><break/>578&#8211;1490 ng.h/mL<break/><bold>Cohort B:</bold><break/>565&#8211;2060 ng.h/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Rimantidine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atmar et al., 1990<break/>[<xref rid="B26-medicina-59-00642" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Rimantadine in water</bold><break/>40 &#181;g/L of air every 15 min to 4 h<break/><bold>Rimantadine in PBS</bold><break/>40 &#181;g/L of air after every 4 h<break/><bold>Rimantadine in water</bold><break/>20 &#181;g/L of air every 4 h to 12 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not stated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Oral:</bold><break/>25.2 h<break/><bold>SPA:</bold><break/>24.1 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Oral:</bold><break/>8193 ng.h/mL<break/><bold>SPA:</bold><break/>1208 ng.h/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Oral:</bold><break/>904 L<break/><bold>SPA:</bold><break/>906 L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Oral:</bold><break/>25.3<break/><bold>SPA:</bold><break/>29.9</td></tr></tbody></table><table-wrap-foot><fn><p>C<sub>max</sub> = maximum concentration, AUC = area under curve, T<sub>1/2</sub> = half-life, V<sub>d</sub> = volume of distribution, Cl = clearance, PKs = pharmacokinetics, LO = Laninamivir Octanoate, T<sub>max</sub> = time to peak drug concentration, BID = two times a day, TID = three times a day, QID = four times a day, PBS = Phosphate buffer solution, SPA = small-particle aerosol.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>